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A term male neonate developed severe intractable lactic acidosis on day of life 1 and died the same day at our institution. The
family previously lost another term, female newborn on day of life 1 from suspected sepsis at an outside hospital. After performing
an autopsy on the neonate who died at our institution, extensive and lengthy neonatal and parental genetic testing, as well as
biochemical analyses, and whole exome sequencing analysis identified compound heterozygous mutations in the lipoyltransferase
1 (LIPT1) gene responsible for the lipoylation of the 2-keto dehydrogenase complexes in the proband. These mutations were also
identified in the deceased sibling. The clinical manifestations of these two siblings are consistent with those recently described in
two unrelated families with lactic acidosis due to LIPT1mutations, an underrecognized and underreported cause of neonatal death.
Conclusions. Our observations contribute to the delineation of a new autosomal recessive metabolic disorder, leading to neonatal
death. Our case report also highlights the importance of an interdisciplinary team in solving challenging cases.
1. Introduction
Neonatal deaths (4.05 per 1,000 US births in 2010) [1]
are devastating for families and the providers. The leading
causes of deaths are congenitalmalformations and conditions
related to prematurity, but often no definitive etiology can be
determined.
Our case report details the investigation of two con-
secutive infants, born to a nonconsanguineous couple after
full-term, otherwise uncomplicated pregnancies, who died
on their first day of life. These two neonatal deaths were
ultimately linked to mutations in the lipoyltransferase 1
(LIPT1) gene. Lipoyltransferase 1 is one of several known
proteins involved in the biosynthesis and function of lipoic
acid. Lipoic acid is an essential cofactor to the activity
of mitochondrial enzymes that comprise four 2-oxoacid
dehydrogenases and the glycine cleavage system [2].
2. Case Presentation
2.1. Case 1. A 2.75 kg term female infant was delivered via
uncomplicated vaginal delivery to a healthy 24-year-old G1
Mexican-American woman. The only pregnancy complica-
tion was maternal hypothyroidism. The infant had Apgar
scores of 5, 6, and 6 at 1, 5, and 10 minutes, respectively.
Cord gases showed moderate metabolic acidosis (venous:
pH of 7.16, PCO
2
of 60, PO
2
of 8.6; arterial blood gas: pH
7.14, PCO
2
60.4, and PO
2
9). The infant’s condition rapidly
deteriorated, with progressive respiratory distress and shock.
The infant ultimately died at 1.5 hours of life. Maternal group
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Table 1: Laboratory evaluation of the proband.
Testing Test Results
Genetic tests
Chromosomal microarray analysis
High resolution identified a copy
number gain of chromosome band
14q24.3 spanning approximately
0.255Mb in a nondisease associated
region. This gain contains at least
five genes and is expected to be
inherited 93% of the time. Parental
studies were not recommended.
CPT1A gene sequencing No known deleterious mutations
Comprehensive mitochondrial
DNA analysis
No large deletions or deleterious
mutations
PC gene sequencing (pyruvate
carboxylase deficiency) No known deleterious mutations
DLAT gene sequencing (pyruvate
dehydrogenase E2 deficiency) No known deleterious mutations
Biochemical analyses
Mitochondrial respiratory chain
enzyme analysis, skin fibroblasts
Deficiencies in mitochondrial
electron transport chain enzymes
not detected
Newborn screen Pattern of elevation consistent withCPT1, otherwise normal
Plasma amino acids
Suggestive of lactic acidemia, very
elevated alanine, and serum glycine
was normal
Pyruvic acid Elevated
Urine organic acids Notable for lactic aciduria, elevated2-OH and 2-oxoacids
CPT1A/CPT1: carnitine palmitoyltransferase 1A.
PC: pyruvate carboxylase.
DLAT: dihydrolipoamide S-acetyltransferase.
B streptococcus screen, resulting after the neonatal death,
was negative. An autopsy detected no abnormality and the
placental gram stainwas negative.The cause of death ascribed
by the coroner’s office was chorionitis due to maternal group
B streptococcus.
2.2. Case 2 (Proband). In light of her prior pregnancy out-
come, the mother was referred to our high-risk obstetrical
clinic for her second pregnancy. Universal carrier screening
showed her to be a carrier for glycogen storage disease type V
and congenital disorder of glycosylation type 1a. The father’s
carrier screening for these two conditions was negative. The
pregnancy was unremarkable other than maternal hypothy-
roidism, which was well controlled.
The patient was born vaginally at our hospital, after
induction of labor for nonreassuring fetal heart tracing and
decreased fetal movements. The 3.5 kg infant was vigorous
at birth and Apgar scores were 8 and 8 at 1 and 5 minutes,
respectively. Initial physical examination was unremarkable.
Cord gases were not obtained.
Within two hours of life, the infant developed pro-
gressive respiratory distress. Examination revealed gasping
respirations and poor perfusion. Capillary blood gas showed
severe metabolic acidosis (pH of 6.80, PCO
2
of 65, and BE
of −27). Chemistry showed blood sugar of 56mg/dL, Na+
145meq/L, K+ 3.9meq/L, Cl− 116meq/L, CO
2
< 5meq/L,
BUN 6mg/dL creatinine 1.4mg/dL, lactate 16mmol/L, pyru-
vate 0.346mmol/L, ammonia 183 𝜇mol/L, AST 141U/L, and
ALT 15U/L. Complete blood count, chest X-ray, and elec-
trocardiogramwere unrevealing. Sepsis evaluation ultimately
proved negative.
Immediate management consisted of tracheal intubation,
umbilical vessels catheterization, administration of broad-
spectrum antibiotics, fluids, a cardiopressor, and alkali with
vitamin B1, with B12 and levocarnitine therapy empirically
started. Alprostadil infusion was discontinued after echocar-
diography showed normal heart and great vessel anatomy.
Hospital course was one of unremitting shocks that failed to
respond to therapeutic measures. Lactate concentration was
29mmol/L at 15 hours of age. The infant expired at 18 hours
of age, shortly after being placed on hemodialysis.
Gross and pathological autopsy examination did not
reveal any diagnostic abnormalities. Newborn screen results,
collected before 12 hours of age, showed tandem mass
spectroscopy abnormalities in the acylcarnitine panel, sug-
gestive of CPT-1 deficiency. Additionally, laboratory tests
were performed to determine possible etiologies (Table 1).
Parents consented to whole exome sequencing (WES), using
DNA samples from patient and both parents, approximately
2 years after the death of the proband. Results of WES
showed that the deceased infant was compound heterozygous
for two nonsense mutations in the LIPT1 gene (c.806G>A
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and c.980T>G). Mutations were in trans, as the c.806G>A
was paternally inherited and the c.980T>G mutation was
maternally inherited.
To ascertain whether the LIPT1 gene mutations were
present in the previously deceased child, we obtained for-
malin fixed paraffin embedded autopsy tissue from the liver
and kidney from the coroner’s office, extractedDNA from the
blocks, and performed targeted LIPT1mutation analysis.The
same LIPT1 gene mutations were found in Case 1, leading us
to believe these gene variants were the cause of the neonates’
death.
2.3. Case 3. While the genetic evaluation of her deceased
children was ongoing, the mother became pregnant while on
birth control.We were able to perform chorionic villous sam-
pling with targeted testing of the identified LIPT1mutations.
The results showed the fetus did not carry any LIPT1mutation
previously detected in the siblings. The third pregnancy
was again only complicated by maternal hypothyroidism,
which was well controlled. She delivered a full-term 4.2 kg
female infant, who is alive and thriving at 12 months of life.
Interestingly, the mother reported significantly more fetal
activity with this pregnancy than in her prior 2 pregnancies.
3. Discussion
Most common etiologies of neonatal shock include hypov-
olemia, asphyxia, cardiac defects, and sepsis. Although less
frequent, inborn errors of metabolism can lead to severe end-
organ dysfunction and neonatal shock [3, 4].
Lactic acidosis is conventionally defined as the concur-
rence of lactate accumulation in excess of 5mmol/L and
a pH < 7.35. While serum lactate can be elevated in a
number of inborn errors of metabolism such as glycogen
storage diseases and fatty acid oxidation disorders, metabolic
disorders associated with severe lactic acidosis point to
abnormalities of pyruvate metabolism or respiratory chain
function [4, 5]. Whether it is the result of inadequate tissue
oxygenation or due to inbornmetabolic disorders, severe and
prolonged lactic acidosis and the resultingmultiorgan energy
failure may prove fatal.
Lipoic acid is an essential cofactor to several cellular redox
reactions and is found in all kingdoms of life. In humans,
lipoic acid is exclusively found in mitochondria and is
essential to the activity of five different enzymatic complexes:
pyruvate dehydrogenase, alpha ketoglutarate dehydrogenase,
2-oxoadipate dehydrogenase, branched chain ketoacid dehy-
drogenase, and the glycine cleavage system [2, 6, 7]. Anumber
of proteins are necessary to the biosynthesis of lipoic acid
and mutations in several genes are known to cause human
diseases [2].
The lipoyl transferase, encoded by LIPT1, participates
in the final steps of lipoate synthesis from octanoate and
is essential to the activity of all aforementioned enzymatic
complexes but the glycine cleavage system.
Tort et al. reported the first patient with mutations of
the LIPT1 gene [8]. After a two-day symptom-free period,
the neonate presented with bradycardia and weight loss, and
her clinical condition worsened over the next several days to
include generalized hypertonia and dystonia and progressive
organ failure leading to her death at 9 days of life. The
sequence analysis of the LIPT1 gene identified two heterozy-
gous missense mutations (c.212C>T and c.292C>G). Shortly
thereafter, Soreze et al. reported another case of LIPT1 gene
mutations in a male infant who developed Leigh disease after
a gastroenteritis episode at 18 months of life [9]. This infant’s
early development was notable for delayed psychomotor
development with hypotonia. Ultimately, the sequence anal-
ysis of LIPT1 gene demonstrated compound heterozygous
mutations (c.875C>G and c.535A>G) in LIPT1 gene. Both
patients had elevated urine lactate and ketoglutarate but
normal serum glycine levels. We herein report a family with
two successively affected neonates with mutations in LIPT1
gene who died of intractable cardiovascular collapse on the
first day of life. A third child, who did not have the LIPT1
mutations that affected her siblings, is alive and well. The
proband had profound lactic acidemia, elevated urine lactate,
ketoglutarate, 2-oxoacids, and normal serum glycine. The
biochemical profile of the proband is consistent with that
observed in the two previously published cases of LIPT1
mutations. The lack of glycine elevation suggests sparing of
the glycine cleavage system, consistent with the fact that
the glycine cleavage system does not depend on LIPT1 for
lipoylation [2].
The reason for heterogeneity of clinical presentation in
these three reports is at present unclear. Mutations reported
differ in all three cases. The infant reported by Tort et al. had
compound heterozygous mutations resulting in substitution
of Ser71 for Phe and of Arg98 for Gly, respectively [8]. The
case reported by Soreze et al. had compound heterozygous
mutations resulting in a stop codon and in the substitution
of Thr179 for Ala [9]. The mutations seen in the present
family introduced two stop codons. Residual activity of
the lipoyltransferase enzyme, heterogeneity of the 2-keto
dehydrogenase complexes activity in different tissues, and yet
to be identified modifiers of enzyme activity may account
for some of the varying clinical presentations. However, the
clinical spectrum of patients with disorders of mitochondrial
function is known to be broad and variable (any tissue, any
symptom, and any age), as is illustrated in the results of recent
Pediatric series [10–12]. As more cases are reported and the
role of lipoic acid in mitochondrial metabolism is further
delineated, we may be able to better understand the clinical
spectrum of LIPT1 gene mutations.
In summary, lipoyltransferase 1 gene defect is associated
with severe mitochondrial dysfunction disrupting lipoic acid
biogenesis. Clinical manifestations associated with defective
lipoic acid metabolism include early seizures, hypotonia,
cardiomyopathy and pulmonary hypertension, and Leigh-
like encephalopathy. In the most extreme cases, they may
result in cardiorespiratory collapse and early neonatal death.
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